RESUMO
Influenza virus infections are a major public health threat. Vaccination is available, but unpredictable antigenic changes in circulating strains require annual modification of seasonal influenza vaccines. Vaccine effectiveness has proven limited, particularly in certain groups, such as the elderly. Moreover, preparedness for upcoming pandemics is challenging because we can predict neither the strain that will cause the next pandemic nor the severity of the pandemic. The European Union fosters research and innovation to develop novel vaccines that evoke broadly protective and long-lasting immune responses against both seasonal and pandemic influenza, underpinned by a political commitment to global public health.
Assuntos
Biotecnologia , Vacinas contra Influenza/imunologia , Influenza Humana/prevenção & controle , Saúde Pública , Pesquisa , União Europeia , Humanos , Vírus da Influenza A/imunologia , Influenza Humana/epidemiologia , VacinologiaAssuntos
Pesquisa Biomédica , Acessibilidade aos Serviços de Saúde , Saúde do Lactente , Saúde Materna , Parto , Qualidade da Assistência à Saúde , Adolescente , Saúde do Adolescente , Adulto , Feminino , Saúde Global , Acessibilidade aos Serviços de Saúde/normas , Acessibilidade aos Serviços de Saúde/tendências , Necessidades e Demandas de Serviços de Saúde , Humanos , Lactente , Mortalidade Infantil , Recém-Nascido , Masculino , Mortalidade Materna , Gravidez , Qualidade da Assistência à Saúde/normas , Qualidade da Assistência à Saúde/tendências , MigrantesRESUMO
Immunisation efforts save millions of lives every year, but vaccines hold the potential to deliver even greater health benefits for mankind. Vaccine research and development is highly complex, and it requires concerted public funding efforts to support. In this paper we discuss EU funding priorities and the resulting recent advancements in European vaccine research, and we lay out the EU strategy for aiding promising vaccine candidates to successfully reach the market.